Company Overview
Company Type: Public Company
Website: www.replicel.com
Number of Employees: 1
Ticker: REPC.F (OTCPK)
Year Founded: 2006


Business Description
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual’s own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company’s product candidates include RCT-01 for the treatment of chronic tendinosis; RCS-01 to treat aging and sun damaged skin; and RCH-01 for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. The company was founded in 2006 and is headquartered in Vancouver, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
0.4
Market Capitalization
7.5
TEV/Total Revenue
21.3x
EBITDA
(1.5)
Total Enterprise Value
7.5
TEV/EBITDA
NM
EBIT
(1.5)
Cash & ST Invst.
0.7
P/Diluted EPS Before Extra
NM
Net Income
(0.9)
Total Debt
0.8
Price/Tang BV
NM
Total Assets
1.1
Total Debt/EBITDA
NM


Currency in CAD in mm, LTM as of Mar-31-2023 TEV and Market Cap are calculated using a close price as of Sep-27-2023

Key Professionals
Name
Title
Schutte, Andrew 
President, CEO & Director
McElwee, Kevin John
Co-Founder & Chief Scientific Officer
Kwok, David 
Chief Financial Officer
Austring, Ben 
Chief Legal Officer, Corporate Secretary & COO
Hoffmann, Rolf 
Chief Medical Officer & Member of Clinical Advisory Board

Key Board Members
Name
Title
Hall, David M.
Independent Chairman of the Board
Schutte, Andrew 
President, CEO & Director
Hoffmann, Rolf 
Chief Medical Officer & Member of Clinical Advisory Board
Davidson, Ross G.
Chairman of Clinical Advisory Board
Lewis, Peter Winston
Independent Director
Boddington, Gary 
Independent Director
Buckler, R. Lee
Director
Krutmann, Jean 
Member of Clinical Advisory Board
Kumai, Tsukasa 
Member of Clinical Advisory Board
MacKay, Jamie 
Director
Morita, Akimichi 
Member of Clinical Advisory Board
Suzuki, Kunihiko 
Senior Strategic Advisor to Directors


Primary Industry Classification
Life Sciences Tools and Services


Primary Office Location
570 Granville Street Suite 900 | Vancouver, BC | V6C 3P1 | Canada
Phone: 604-248-8730   Fax: 604-248-8690

Current and Pending Investors
Berkley Renewables Inc., MainPointe Pharmaceuticals, LLC, Summer Street Research Partners, Asset Management Arm, YOFOTO (China) Health Industry Co. Ltd.

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.12
Market Cap (mm)
7.6
Open
 0.12
Shares Out. (mm)
65.0
Previous Close
 0.12
Float %
35.5%
Change on Day
(0.01)
Shares Sold Short (mm)
0.0
Change % on Day
(10.1)%
Dividend Yield %
-
Day High/Low
 0.12/ 0.12
Diluted EPS Excl. Extra Items
(0.02)
52 wk High/Low
 0.26/ 0.07
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0003
Avg 3M Dly Vlm (mm)
0.0021
Beta 5Y
1.06


 
Delayed Quote** | Last Updated on Sep-27-2023 12:00 AM (GMT-5)
OTCPK:REPC.F - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
583885 B.C. Ltd.
As of December 22, 2010, 583885 B.C. Ltd. operates as a subsidiary of RepliCel Life Sciences Inc.

United States and Canada
-
-
-
-
Newcastle Resources Ltd.
As of December 22, 2010, Newcastle Resources Ltd. was acquired by TrichoScience Innovations Inc., in a reverse merger transaction. Newcastle Resources Ltd., an exploration stage company, engages in sourcing and exploring mineral properties in Canada. It holds 100% interests in the Lennie property, a gold exploration project located in the Red Lake Mining District of Ontario, Canada. The company was formerly known as Pan American Gold Corporation and changed its name to Newcastle Resources Ltd. in November 2008. Newcastle Resources Ltd. is based in Vancouver, Canada.

United States and Canada
Gold
-
0.00
0.00
TrichoScience Innovations Inc

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Feb-02-2023
Feb-08-2023
Private Placement
Target
RepliCel Life Sciences Inc. (OTCPK:REPC.F)


0.01
Jan-26-2023
Mar-14-2023
Private Placement
Target
RepliCel Life Sciences Inc. (OTCPK:REPC.F)


0.74
Jan-17-2023
Jan-26-2023
Private Placement
Target
RepliCel Life Sciences Inc. (OTCPK:REPC.F)


0.09
Sep-06-2022
Jan-03-2023
Private Placement
Target
RepliCel Life Sciences Inc. (OTCPK:REPC.F)


0.62
Mar-21-2022
May-04-2022
Private Placement
Target
RepliCel Life Sciences Inc. (OTCPK:REPC.F)


0.59
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-22-2023
Annual General Meeting
RepliCel Life Sciences Inc., Annual General Meeting, Sep 22, 2023
Sep-22-2023
Shareholder/Analyst Calls
RepliCel Life Sciences Inc. - Shareholder/Analyst Call
Aug-30-2023
Executive/Board Changes - Other
Replicel Life Sciences Inc. Announces That Peter Lowry Will Not Be Standing for Re-Election as A Director
Aug-17-2023
Executive/Board Changes - Other
RepliCel Life Sciences Inc. Appoints Jamie Mackay to the Board of Directors
Aug-17-2023
Executive Changes - CFO
RepliCel Life Sciences Inc. Announces Chief Financial Officer Changes

M&A Advisors
Borden Ladner Gervais LLP, Clark Wilson LLP


Advisors
Most Recent Auditor
Mao & Ying LLP
M&A Advisors
Borden Ladner Gervais LLP, Clark Wilson LLP
Private Placement Advisors
Clarus Securities Inc., Echelon Wealth Partners Inc., GundyCo, Haywood Securities Inc., Jones, Gable, & Company Limited, Leede Jones Gable Inc., Raymond James Ltd., Richardson GMP Limited, Investment Banking Arm, Wolverton Securities Ltd


Most Recent Auditor
Mao & Ying LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

03:28 AM
REPC.F
Replicel Life Sciences Inc 2023_10_05
Reports
14
MarketLine

Sep 20, 2023 06:01 AM
REPC.F
RepliCel Life Sciences Inc
Reports
30
S&P Global Compustat

Sep 07, 2023 03:13 AM
REPC.F
Replicel Life Sciences Inc 2023_09_07
Reports
14
MarketLine

Aug 31, 2023 06:01 AM
REPC.F
RepliCel Life Sciences Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Reports
301
S&P Global Compustat

Jul 06, 2023 02:49 AM
REPC.F
Replicel Life Sciences Inc 2023_07_06
Reports
14
S&P Global Compustat

Jun 01, 2023 03:23 AM
REPC.F
Replicel Life Sciences Inc 2023_06_01
Reports
14
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
May 26, 2023 06:37 AM
REPC.F
Rating Update for Replicel Life Sciences Inc
EPS Estimates*
3
Wright Investors' Service Inc.

May 24, 2023 01:41 AM
REPC.F
Flow of Funds Report for RepliCel Life Sciences Inc - prepared by Wright Investors Service
Notes
66
S&P Global Compustat

May 04, 2023 03:05 AM
REPC.F
Replicel Life Sciences Inc 2023_05_04
Reports
14
S&P Global Compustat

Apr 06, 2023 03:36 AM
REPC.F
Replicel Life Sciences Inc 2023_04_06
Reports
14


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Schutte, Andrew 

17,401,616

26.77

2.0

Aug-16-2023


MacKay, Jamie 

10,034,537

15.44

1.2

Aug-16-2023


YOFOTO (China) Health Industry Co. Ltd.

5,357,900

8.24

0.6

Apr-25-2023


MainPointe Pharmaceuticals, LLC

3,986,684

6.13

0.5

Apr-25-2023


McElwee Ph.D., Kevin John

1,329,245

2.04

0.2

May-08-2023


Lowry, Peter 

1,193,426

1.84

0.1

May-08-2023


Hall B.A., B.Com., David M.

875,632

1.35

0.1

Aug-16-2023


Lewis C.A., CA, Peter Winston

626,920

0.96

0.1

Aug-16-2023


Hoffmann M.D., Rolf 

489,572

0.75

0.1

Apr-25-2023


Austring, Ben 

320,500

0.49

0.0

May-08-2023



 



Top Buyers
No Top Buyers data available.

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Ma B.A., C.A., CPA, CA, Simon S.
0
(7,460)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
DermaPrecise Injector (Future), Licensing of RCI-02, Licensing of RCS-01, Licensing of RCT-01, RCH-01 (Future), RCI-02 (Future), RCS-01 (Future), RCT-01 (Future)


Upcoming Events
Date/Time
Type
Nov-28-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Oct-04-2023
Sep-30-2023
RepliCel Life Sciences Inc. (OTCPK:REPC.F)
SEC
6-K
42 KB
Oct-03-2023
-
RepliCel Life Sciences Inc. (OTCPK:REPC.F)
SEDAR
Material Change Report
80 KB
Sep-27-2023
-
RepliCel Life Sciences Inc. (OTCPK:REPC.F)
SEDAR
News Releases
164 KB
Sep-14-2023
Sep-13-2023
RepliCel Life Sciences Inc. (OTCPK:REPC.F)
SEC
6-K
47 KB
Sep-13-2023
-
RepliCel Life Sciences Inc. (OTCPK:REPC.F)
SEDAR
Material Change Report
81 KB
Sep-13-2023
-
RepliCel Life Sciences Inc. (OTCPK:REPC.F)
SEDAR
News Releases
148 KB
Sep-13-2023
-
RepliCel Life Sciences Inc. (OTCPK:REPC.F)
SEDAR
News Releases
155 KB
Sep-07-2023
Aug-31-2023
RepliCel Life Sciences Inc. (OTCPK:REPC.F)
SEC
6-K
36 KB
Aug-31-2023
-
RepliCel Life Sciences Inc. (OTCPK:REPC.F)
SEDAR
Material Change Report
82 KB
Aug-30-2023
Sep-22-2023
RepliCel Life Sciences Inc. (OTCPK:REPC.F)
SEC
6-K
2 MB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Schutte, Andrew  (President, CEO & Director)
Mar-14-2023
Common Shares
4,042,500
406,013
Private Acquisition
30.26
Multiple
MacKay, Jamie  (Director)
Mar-14-2023
Common Shares
4,021,500
403,904
Private Acquisition
66.88
Multiple
Hall B.A., B.Com., David M. (Independent Chairman of the Board)
Feb-01-2023
Common Shares
17,500
1,895
Private Acquisition
2.04
Multiple
Lewis C.A., CA, Peter Winston (Independent Director)
Feb-01-2023
Common Shares
17,500
1,895
Private Acquisition
2.87
Multiple
Schutte, Andrew  (President, CEO & Director)
Feb-01-2023
Common Shares
116,666
12,633
Private Acquisition
0.88
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Hall, David M.
Independent Chairman of the Board
604-248-8730
604-248-8690

Schutte, Andrew 
President, CEO & Director
604-248-8730
604-248-8690

Hoffmann, Rolf 
Chief Medical Officer & Member of Clinical Advisory Board
604-248-8730
604-248-8690

Davidson, Ross G.
Chairman of Clinical Advisory Board
604-248-8730
604-248-8690
-
Lewis, Peter Winston
Independent Director
604-248-8730
604-248-8690

Boddington, Gary 
Independent Director
604-248-8730
604-248-8690

Buckler, R. Lee
Director
604-248-8693
(604) 248-8690
lee@replicel.com
Krutmann, Jean 
Member of Clinical Advisory Board
604-248-8730
604-248-8690

Kumai, Tsukasa 
Member of Clinical Advisory Board
604-248-8730
604-248-8690

MacKay, Jamie 
Director
604-248-8730
604-248-8690

Morita, Akimichi 
Member of Clinical Advisory Board
604-248-8730
604-248-8690

Suzuki, Kunihiko 
Senior Strategic Advisor to Directors
604-248-8730
604-248-8690

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Schutte, Andrew 
President, CEO & Director
604-248-8730
604-248-8690

McElwee, Kevin John
Co-Founder & Chief Scientific Officer
604-248-8730
604-248-8690

Kwok, David 
Chief Financial Officer
604-248-8730
604-248-8690

Austring, Ben 
Chief Legal Officer, Corporate Secretary & COO
604-248-8730
604-248-8690

Hoffmann, Rolf 
Chief Medical Officer & Member of Clinical Advisory Board
604-248-8730
604-248-8690

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
